- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07617350
Study of the Subdermal Implant "Ultracol"
A Single-center Clinical Study of the Efficacy and Safety of the Medical Device "Intradermal Implant, Sterile ULTRACOL Based on Polydioxanone (ULTRA V Co., Ltd., Korea) in the Correction of Skin Contour Defects.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The investigational product is composed of a mixture of polydioxanone and sodium carboxymethylcellulose. The polydioxanone content is as follows: Ultracol 200: 150 mg ±10%, Ultracol 100: 75 mg ±10%. The key difference from the closest analogs (AestheFill® V200, Sculptra™, Ellagen PLLA+CMC 1000 mg) is the presence of polydioxanone in the investigational product.
Thus, the analyzed analogues are not fully interchangeable medical products. The combined composition of Ultracol has not been studied properly. Therefore, during the clinical study, it is necessary to check the safety and effectiveness of a medical product with a combined composition - polydioxanone and sodium carboxymethylcellulose.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Russia
-
Moscow, Russia, Ryssland, 119034
- Estelab CLinic
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- The subject has indications for use according to the manufacturer instructions for the device.
- The subject is at least 18 years old at the time of signing the informed consent.
- The subject expresses willingness and ability to follow the requirements of the study protocol.
- The subject has no contraindications described in the device instructions for use.
Exclusion Criteria:
- The subject has at least one contraindication described in the device instructions for use, based on initial examination, laboratory tests and medical history.
- Women of reproductive age: pregnancy, planning pregnancy during the study period, or breastfeeding.
- Use of another product for the same indication during the clinical study.
- Participation in another clinical study.
- Pre-existing health problems that may compromise compliance with the study protocol.
- Patients prone to excessive scarring.
- Patients undergoing chemotherapy.
- Patients previously treated with intradermal fillers in the planned injection zone with persistent effect.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Experimental Group
ULTRACOL Intradermal Implant (Polydioxanone-based).
All 23 adult subjects (22 female, 3 male; mean age 51.1, range 37-70) received intradermal injections of ULTRACOL using linear-retrograde technique into the lower dermis or hypodermis.
ULTRACOL 100 (100 mg/vial, reconstituted in 1 mL water for injection) used in all 23 patients; ULTRACOL 200 (200 mg/vial, reconstituted in 2 mL water for injection) used in 20 patients.
Mean 1.87 injections per patient.
Maximum dose: 3 mL per procedure.
Treatment zones: nasolabial folds, cheeks, zygomatic area, perioral/periauricular regions, facial oval.
Follow-up: Day 30, 60, 160.
|
Lyophilized intradermal implant based on polydioxanone (PDO) and sodium carboxymethylcellulose (Na-CMC).
ULTRACOL 100: 100 mg/vial (75 mg PDO), reconstituted in 1 mL water for injection.
ULTRACOL 200: 200 mg/vial (150 mg PDO), reconstituted in 2 mL water for injection.
Administered intradermally using linear-retrograde technique.
Maximum dose: 3 mL per procedure.
Mean 1.87 injections per subject.
Manufactured by ULTRA V Co., Ltd., Republic of Korea.
Class III medical device.
Biostimulating mechanism: PDO hydrolysis stimulates neocollagenesis.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Wrinkle Severity Rating Scale (WSRS) Score
Tidsram: Baseline, Day 30, Day 60, Day 160 after first injection
|
Validated 5-point scale (1 = no wrinkles, 5 = extreme wrinkles) assessed by the investigator.
A reduction of 1 or more points compared to baseline is considered clinically significant.
Units: Score on a scale (1-5).
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Baker Ptosis Classification
Tidsram: Baseline, Day 30, Day 60, Day 160 after first injection
|
4-grade classification of facial soft tissue ptosis assessed by the investigator (Grade I = minimal, Grade IV = severe).
Unit: Score on a scale (I-IV).
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
|
Global Aesthetic Improvement Scale (GAIS) - Investigator Assessment
Tidsram: Day 30, Day 60, Day 160 after first injection
|
5-point Global Aesthetic Improvement Scale (0 = worse, 1 = no change, 2 = improved, 3 = much improved, 4 = very much improved) assessed by the investigator.
Unit: Score on a scale (0-4).
|
Day 30, Day 60, Day 160 after first injection
|
|
Global Aesthetic Improvement Scale (GAIS) - Subject Self-Assessment
Tidsram: Day 30, Day 60, Day 160 after first injection
|
5-point Global Aesthetic Improvement Scale (0 = worse, 4 = very much improved) assessed by the subject.
Unit: Score on a scale (0-4).
|
Day 30, Day 60, Day 160 after first injection
|
|
Change in Perceived Age (Subject Self-Assessment)
Tidsram: Baseline, Day 30, Day 60, Day 160 after first injection
|
Subject self-assessment of perceived age before and after treatment.
A reduction of at least 1 year is considered clinically meaningful.
Unit: Years.
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
|
Change in Skin Parameters by Multi-Parametric Ultrasound
Tidsram: Baseline and Day 160 after first injection
|
Multi-parametric facial skin ultrasound assessing: epidermis thickness (mm), papillary dermis thickness (mm), reticular dermis thickness (mm), subcutaneous fat thickness (mm), vascularization index (%), dermis stiffness via compression elastography (kPa).
Unit: Combined imaging parameters reported per individual measurement (mm / % / kPa).
|
Baseline and Day 160 after first injection
|
|
Change in Lemperle Scale (Nasolabial Fold Depth)
Tidsram: Baseline, Day 30, Day 60, Day 160 after first injection
|
5-point Lemperle scale for assessment of nasolabial fold depth (0 = no wrinkle, 5 = very deep wrinkle), assessed by the investigator.
Unit: Score on a scale (0-5).
|
Baseline, Day 30, Day 60, Day 160 after first injection
|
|
Number of Participants with Adverse Events (AEs) and Adverse Device Effects (ADEs)
Tidsram: From first injection through Day 160 (160-day follow-up)
|
Frequency and severity of adverse events (AEs) and adverse device effects (ADEs), assessed by the investigator and recorded throughout the study.
Unit: Number of Participants.
|
From first injection through Day 160 (160-day follow-up)
|
|
Number of Participants with Serious Adverse Events (SAEs) and Serious Adverse Device Effects (SADEs)
Tidsram: From first injection through Day 160 (160-day follow-up)
|
Frequency of serious adverse events (SAEs) and serious adverse device effects (SADEs), assessed by the investigator and recorded throughout the study.
Unit: Number of Participants.
|
From first injection through Day 160 (160-day follow-up)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 060-КИ-МИ-2024
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .